<i>Advanced Therapeutics</i> – from Drug‐Delivering Microrobots to Artificial Intelligence in Digital Health

As we are entering our third year of publication, it is time to review what has happened in year 2 of Advanced Therapeutics and what next steps are planned. In our second volume, we've continued our successful series of monthly issues since the launch of the journal in May 2018, thus resulting in 12 more issues with loads of top-level original research articles, high-quality Reviews and Progress Reports, including interesting and often colorful designs on the front cover, as can be seen in Figure 1. We are very pleased to let you know that we have now received confirmation that Advanced Therapeutics has been accepted into the Emerging Sources Citation Index (ESCI, Clarivate Analytics), such that you will be able to discover all of this content easily through the Web of Science soon. In the first quarter of 2019 we created an online collection with our best articles published to date. The Advanced Therapeutics Editors’ Choice collection shows the full diversity of the different topics that we cover in the journal: from microrobots for drug delivery to an artificial intelligence-driven drug delivery platform (CURATE.AI) and drug nanorods for leukemia treatment. The collection can be accessed here and articles are free to read for a limited time. The high quality of these articles is highlighted by close to 100 accumulated citations in Crossref. We hope you enjoy reading these papers and we encourage you to come back as we plan to update this online collection on a regular basis. Many of these papers can also be found in the top-10 most read papers in the journal in 2019 (see Table 1). Adv. Therap. 2019, 2, 1800064 DOI: 10.1002/adtp.201800064 Adv. Therap. 2019, 2, 1800114 DOI: 10.1002/adtp.201800114 Adv. Therap. 2019, 2, 1900023 DOI: 10.1002/adtp.201900023 Adv. Therap. 2019, 2, 1800091 DOI: 10.1002/adtp.201800091 Adv. Therap. 2019, 2, 1800095 DOI: 10.1002/adtp.201800095 Adv. Therap. 2019, 2, 1800128 DOI: 10.1002/adtp.201800128 Adv. Therap. 2019, 2, 1800090 DOI: 10.1002/adtp.201800090 Adv. Therap. 2019, 2, 1800088 DOI: 10.1002/adtp.201800088 Adv. Therap. 2019, 2, 1800100 DOI: 10.1002/adtp.201800100 Adv. Therap. 2019, 2, 1800087 DOI: 10.1002/adtp.201800087 While downloads and citations might be good proxies for the impact that publications have within the scientific community, societal influence can be measured with the Altmetric Attention Score. In this regard, we would like to congratulate the authors listed in Table 2, whose articles appearing in Advanced Therapeutics in 2019 have gained a lot of traction in many news outlets as well as on social media. Adv. Therap. 2019, 2, 1900133 DOI: 10.1002/adtp.201900133 Adv. Therap. 2019, 2, 1900023 DOI: 10.1002/adtp.201900023 Adv. Therap. 2019, 2, 1900066 DOI: 10.1002/adtp.201900066 An international, interdisciplinary journal can only flourish if its authorship is as diverse as possible. Therefore, we strive to have a globally balanced distribution of authors. Figure 2 shows a geographic visualization of where the corresponding authors of all published articles are based. Top countries are the United States, China, Germany, Australia, and South Korea, followed by Canada and the United Kingdom. From the editorial perspective, the journal has seen a change at the reigns in 2019 – Lorna Stimson has moved to a new role at Wiley-VCH as Publishing Director, Germany. As a result, Christine Mayer has agreed to take over the role of Editor-in-Chief of Advanced Therapeutics. Chris received her PhD in microbiology and biochemistry from the University Innsbruck – Faculty of Medical Chemistry & Biochemistry. In 1997–2001, she worked as a postdoctoral fellow at the Massachusetts Institute of Technology in the area of protein engineering, followed by a second postdoctoral position at the DKFZ in Heidelberg (Germany), where she focused on the analysis of translational cancer drugs and epigenetics. After leaving academia, Chris joined Wiley in 2009. Looking forward to the new year, early 2020 we will be publishing two special issues on “Nanomedicine: Therapeutic Applications”, guest-edited by Xue Xue (Nankai University, Tianjin, China) and Xing-Jie Liang (National Center for Nanoscience and Technology, Beijing, China), and on “Artificial Intelligence for Precision Medicine and Digital Health”, guest-edited by one of our Editorial Advisory Board members, Dean Ho (National University of Singapore). Watch this space! Open Access publication is becoming ever more important. A landmark agreement was signed in January 2019 between Wiley and Projekt DEAL which provides Open Access publication in and read access to most of Wiley's journals to a vast majority of German academic institutions. Advanced Therapeutics, together with the other journals in the Advanced family, is covered by this agreement. It allows corresponding authors based at these German institutions to publish their articles in our journal under an Open Access license, while costs are covered by their institutions under this agreement. Learn more about the agreement with Projekt DEAL here and find out if your institution is a participant in this or other national Open Access programs at Wiley here. In the academic community there is also an increased interest for researchers to share and archive their data, with many funders now mandating data publication. The sharing of data enables others to re-use experimental results and supports the creation of new work built on previous findings, improving the efficiencies of the research process and supporting the critical goals of transparency and reproducibility. In Advanced Therapeutics, we encourage supporting the growing movement to make research more open, because this leads to a fairer, more efficient, and accountable research landscape, which will ultimately drive a more effective and faster pace of discovery. We are committed to improving openness, transparency, and reproducibility of research. Peer review is at the core of the academic publication culture. It is fitting to acknowledge reviewers who give their expertise and time freely to support our journals in this process. The top reviewers for Advanced Therapeutics in 2019 are (in alphabetical order): Eric Andrew Appel, James Henderson, Ulrich Lächelt, Daniel Siegwart, Qiangbin Wang, Xuehai Yan, Alexander N. Zelikin, and Liangfang Zhang. In this context, we are happy to announce that Advanced Therapeutics now offers the option to have your activities as a reviewer recorded on your ORCID profile. To receive credit for your review, please opt in to this feature when you submit your reviewer report to the editorial office. In order to not disclose the identity of the reviewers, ORCID will not reveal any details on individual manuscripts. In addition, posting of recognition to ORCID will be delayed in order to mask the exact date on which the review was completed. Of course, we would also like to express our gratitude for your interest in Advanced Therapeutics, as our authors, our Editorial Advisory Board members, and – last but not least – our readers. We wish you a peaceful, joyful, successful, and healthy new year 2020! The editorial team of Advanced Therapeutics

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.